In the evolving field of biochemical research, the study of synthetic compounds and their interactions with biological receptors remains a cornerstone for scientific discovery. One such compound that has garnered significant attention in laboratory settings is the ZP10A peptide. Often referred to in literature by its various designations—including Lixisenatide, AVE0010, and Lyxumia—this molecule serves as a critical tool for researchers investigating complex metabolic signaling pathways.
Defining ZP10A Peptide and Its Scientific Context
At its fundamental level, ZP10A peptide is recognized as a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist. Structurally, it is a C-terminal amidated peptide designed to mimic the action of endogenous hormones that regulate glucose metabolism. Because Lixisenatide (ZP10A peptide) possesses a high affinity for the GLP-1 receptor, it has become a standard reagent in molecular biology to study insulin signaling and cellular responses.
From a structural perspective, Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is an exendin-4 analogue. Its development was focused on creating a stable, potent agonist that could be utilized in controlled environments to observe how specific peptides bind to their target receptors. In scientific literature, it is often noted that ZP10A is a potent GLP-1 rece Lixisenatide CAS#320367-13-3 | CAS Substance Database ptor agonist, which allows researchers to probe the mechanisms behind insulin secretagogue functions in various model systems.
Key Observations in Biochemical Studies
Much of the interest surrounding ZP10A stems from its performance in preclinical data. Researchers have observed that ZP10A demonstrated dose-dependent improvement of glucose tolerance in experimental models. Furthermore, studies have highlighted that ZP10A increases insulin mRNA expression an May 2, 2013—“Glucagon-likepeptide1 receptor agonistZP10Aincreases insulin mRNA expression and prevents diabetic progression in db/db mice.” J Pharmacol Read more d plays a role in ≥95% (HPLC), Exendin-4-derived glucagon-like peptide-1 preserving cellular function within pancreatic models.
Because Lixisenatide is a once-daily injectable GLP-1 receptor agonist in clinical contexts, its availability as a high-purity research chemical Receptors for glucagon-like peptide-1(7–36) amide on rat (oft lixisenatide MeSH Supplementary Concept Data 2025 en $\geq$95% purity via HPLC) allows labs to conduct precise dose-response experiments. The data indicates that Glucagon-like peptide 1 receptor agonist ZP10A is a valuable asset for those mapping out the protein-protein interactions that occur when a ligand binds to a G-protein-coupled receptor.
Research Applications and Utility
Scientists utilizing ZP10A peptide often focus on the following areas:
* Receptor Binding Assays: Utilizing ZP10A peptide ELISA kits to quantify r by LL Nielsen·2005·Cited by 184—ThorkildsenC.Glucagon-like peptide 1 receptor agonist ZP10Aincreases insulin mRNA expression and prevents diabetic progression in db/db mice. J. Pharmacol Read more eceptor density and ligand affinity.
* Metabolic Signaling: Exploring how Lixisenatide (AVE0010, ZP10A) influences the downstream pathways of the GLP-1 receptor.
* Peptide Synthesis: Studying the C-terminal amidated structure of the peptide to understand how structural modifications affect biological stability.
It is worth noting that Lixisenatide is a peptide-based compound utilized in advanced biochemical research to explore glucose metabolism. Whether referred to as AVE-0010 (ZP-10) or simply ZP10A, the compound remains a subject of intense study. Many investigators view it as a benchmark, noting that ZP10A is considered one of the most promising new drug candidates for understanding the modulation of metabolic hormones.
Conclusion
The study of Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 Read more zp10a peptide continues to provide deep insights into how synthetic agonists can be engineered to interact with human receptors. By maintaining rigorous standards in the lab—ensuring the use of high-quality reagents—researchers can continue to verify how these compounds affect insulin signaling. As we look at the broader landscape of Peptide 1 Receptor Agonist ZP10A research, it is clear that this molecule, which is used to control blood sugar levels in broader pharmaceutical applications, remains one of the most significant tools for those working to decode the intricacies of metabolic regulation.